real-world evidence

Editorial Message

11/01/2022

Dr. John C. Lantis II, Clinical Editor, considers the importance of--and difficulty in collecting--real-world data related to patients outcomes.

Dr. John C. Lantis II, Clinical...

11/01/2022

Wounds

Guest Editorial

We Can Help Drive Acceptance of Real-World Evidence

04/01/2022

Marcia I. Nusgart , RPh;

Now is a unique time for clinicians to articulate the realities and complexities of wound care.

Now is a unique time for...

04/01/2022

Wound Management & Prevention

Videos

Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer

02/25/2021

Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.

Stephen Freedland, MD, discusses...

02/25/2021

Journal of Clinical Pathways

Videos

Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma

02/19/2021

Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.

Shilpa Gupta, MD, discusses the...

02/19/2021

Journal of Clinical Pathways

Videos

PTEN Loss of Function Associated With Worse Survival in Metastatic CRPC

02/18/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Cardiotoxicity of Abiraterone vs Enzalutamide for Prostate Cancer

02/15/2021

Journal of Clinical Pathways

News

Real-World Costs of First-Line Prostate Cancer Management Strategies

01/05/2021

Journal of Clinical Pathways

News

Use of Real-World EHR to Identify Disparities for COVID-19 in Patients With Cancer

01/05/2021

Journal of Clinical Pathways

Videos

Real-World Biomarker Testing, Treatment Patterns in CLL/SLL

12/17/2020

Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.

Anthony Mato, MD, discusses...

12/17/2020

Journal of Clinical Pathways

Conference Coverage

Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting

12/06/2020

Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.

Results from a real-world study...

12/06/2020

Journal of Clinical Pathways